Virtual Charcot-Marie-Tooth Examination Score
A Validated Virtual Evaluation for People With Charcot-Marie-Tooth Disease
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received April 5, 2022
- Accepted June 27, 2022
- First Published August 31, 2022.
Article Versions
- Previous version (August 31, 2022 - 12:45).
- You are viewing the most recent version of this article.
Author Disclosures
- Valeria Prada, PhD, PT,
- Matilde Laurà, MD, PhD,
- Riccardo Zuccarino, MD, PhD,
- Mary M. Reilly, MD and
- Michael E. Shy, MD
- Valeria Prada, PhD, PT,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Matilde Laurà, MD, PhD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Riccardo Zuccarino, MD, PhD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Mary M. Reilly, MD and
Commercial<br><br>1. Eidos steering committee
NONE
None
(1) Neuromuscular Disorders, Editorial Board (current)<br>(2) European Journal of neurology, editorial board (current)
NONE
NONE
NONE
(1)Commercial entity:<br>Occasional consultancy for Alynam,<br>Inflectis, IONIS and Akcea
1. Commercial Alnylam Symposium EAN 2021
NONE
NONE
NONE
NIH grantS U54NS065712, 1UOINS109403-01, R21TR003034<br>MRC grant MR/S005021/1
•MDA grant (MDA510281) Muscle MRI in Charcot Marie <br>Tooth disease (PI) 2017-2021<br>CMTA grants for CMT1B,2A and 1X
None
NONE
NONE
NONE
NONE
NONE
NONE
- Michael E. Shy, MD
(1) Charcot Marie Tooth Association-Non Profit<br>(2) Muscular Dystrophy Association (MDA)-Non Profit
Applied Therapeutics Commercial entity for developing a <br>treatment trial for a peripheral neuropathy. Not relevant to <br>the current study
None
Neuromuscular Disorders, Editorial Board<br>Muscle and Nerve, Editorial Board
NONE
NONE
NONE
(1) Alnylam Pharmaceuticals - Consultant<br>(2) Mitochondria in Motion-Consultant<br>(3) Inflectis BioSci - Consultant<br>(4) Neurogene - Consultant<br>(5) Applied Therapeutics - (Consultant)
NONE
NONE
NONE
NONE
NINDS/Office of Rare Disease/NCATS
NONE
(1) Muscular Dystrophy Association;<br>(2) Charcot Marie Tooth Association
NONE
NONE
NONE
NONE
NONE
NONE
- From the University of Iowa (V.P., M.E.S.), Carver College of Medicine, Iowa City, IA; FISM (V.P.), Fondazione italiana Sclerosi Multipla, Genova, Italy; Department of Neuromuscular Diseases (M.L., M.M.R.), UCL Queen Square Institute of Neurology and National Hospital for Neurology and Neurosurgery, London, United Kingdom; and Centro Clinico NeMO Trento (R.Z.), Fondazione Serena ONLUS, Pergine Valsugana (Trento), Italy.
- Correspondence
Dr. Prada valeria.prada{at}gmail.com
Article usage
The Nerve!: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
- No related articles found.